Recurrent Pericarditis
4
Pipeline Programs
1
Companies
4
Clinical Trials
1 recruiting
1
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
1
1
Early DiscoveryClinical DevelopmentMarket
On Market (1)
Approved therapies currently available
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Kiniksa PharmaceuticalsMA - Lexington
4 programs2
1
1
RilonaceptPhase 31 trial
KPL-387Phase 21 trial
KPL-914Phase 21 trial
REgiStry Of the NAtural History of recurreNt periCarditis in pEdiatric and Adult PatientsN/A1 trial
Active Trials
+1 more trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
2029
Kiniksa PharmaceuticalsRilonacept
Kiniksa PharmaceuticalsKPL-387
Kiniksa PharmaceuticalsKPL-914
Kiniksa PharmaceuticalsREgiStry Of the NAtural History of recurreNt periCarditis in pEdiatric and Adult Patients
Clinical Trials (4)
Total enrollment: 692 patients across 4 trials
Study to Assess the Efficacy and Safety of Rilonacept Treatment in Participants With Recurrent Pericarditis
Start: Jan 2019Est. completion: Jun 202286 patients
Phase 3Completed
Transition to KPL-387 Monotherapy Dosing & Administration Study
Start: Jan 2026Est. completion: Dec 202980 patients
Phase 2Recruiting
A Pilot Study of KPL-914 in Recurrent Pericarditis
Start: Jan 2018Est. completion: May 201926 patients
Phase 2Completed
NCT04687358Kiniksa PharmaceuticalsREgiStry Of the NAtural History of recurreNt periCarditis in pEdiatric and Adult Patients
REgiStry Of the NAtural History of recurreNt periCarditis in pEdiatric and Adult Patients
Start: Mar 2021Est. completion: Mar 2029500 patients
N/AActive Not Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 692 patients
1 companies competing in this space